Withonly limited SBIR involvement, the founders of bioProtonics are longtime experienced directing and managing development efforts in areas as diverse as materials systems, semiconductor detectors, signal processing, pharmaceuticals, point-of-care biosensors, and biomedical imaging. The firm's current efforts (µTexture in vivo) organize around in vivo, MR-based diagnostic designed to provide the resolving power needed to measure the ultra fine tissue changes that are (often) the earliest harbingers of disease, thus enabling most effective application of therapeutics.
